CTKB Cytek Biosciences PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: CTKB
- PE Ratio
The PE ratio for Cytek Biosciences stock stands at 0.0 as of Jul 3, 2025. This takes into account the latest EPS of $16,603.78 and stock price of $3.76.
CTKB PE ratio history
Over the last four years, the average PE ratio of Cytek Biosciences has been 263.5. The current 0.0 price-to-earnings ratio is 100% less than the historical average. Analyzing the last four years, CTKB's PE ratio reached its highest point in the Sep 2021 quarter at 1,070.5, with a price of $21.41 and an EPS of $0.02. The Mar 2024 quarter saw the lowest point at 0, with a price of $6.71 and an EPS of $11,194.83.
Cytek Biosciences PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $6.49 | -$0.05 |
| 2023 | N/A | N/A | $9.12 | -$0.09 |
| 2022 | 510.5 | N/A | $10.21 | $0.02 |
| 2021 | N/A | N/A | $16.32 | $0 |
| 2020 | N/A | N/A | N/A | $0.11 |
| 2019 | N/A | N/A | N/A | -$0.8 |
Cytek Biosciences PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | 0 | N/A | $4.01 | $16,603.78 |
| Dec 2024 | N/A | N/A | $6.49 | -$0.05 |
| Sep 2024 | 0 | N/A | $5.54 | $18,591.78 |
| Jun 2024 | 0 | N/A | $5.58 | $11,194.78 |
| Mar 2024 | 0 | N/A | $6.71 | $11,194.83 |
| Dec 2023 | N/A | N/A | $9.12 | -$0.09 |
| Sep 2023 | N/A | N/A | $5.52 | -$6,456.05 |
| Jun 2023 | N/A | N/A | $8.54 | -$0.04 |
| Mar 2023 | N/A | N/A | $9.19 | -$0.01 |
| Dec 2022 | 510.5 | N/A | $10.21 | $0.02 |
| Sep 2022 | N/A | N/A | $14.72 | -$0.01 |
| Jun 2022 | N/A | N/A | $10.73 | -$0.02 |
| Mar 2022 | N/A | N/A | $10.78 | -$0.02 |
| Dec 2021 | N/A | N/A | $16.32 | $0 |
| Sep 2021 | 1,070.5 | N/A | $21.41 | $0.02 |
CTKB Price vs fair value
CTKB average PE ratio chart
CTKB's current PE ratio is under its 3-year average.
CTKB PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| CTKB Cytek Biosciences Inc | 0 | $476.24M |
| OBIO Orchestra BioMed Holdings Inc | N/A | $110.72M |
| OM Outset Medical Inc | N/A | $370.4M |
Frequently asked questions
What is Cytek Biosciences's PE ratio?
As of Jul 3, 2025, CTKB stock has a price to earnings ratio of 0.
What is the 3-year average PE ratio for Cytek Biosciences (CTKB)?
The average PE ratio for CTKB stock over the past 3 years is 102.1.
What is the highest PE ratio for CTKB?
Over the last four years, the quarterly PE ratio reached its highest level at 1,070.5 in the Sep 2021 quarter.
How does the current PE ratio for CTKB compare to its historical average?
CTKB's price to earnings ratio is currently 100% below its 4-year historical average.
Why is Cytek Biosciences's PE ratio so low?
CTKB's PE ratio of 0 is considered low because the company's stock price is trading at a lower multiple of earnings.
How is CTKB's PE ratio calculated (Cytek Biosciences PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jul 3, 2025), Cytek Biosciences's share price is $3.76. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $16,603.78. Therefore, Cytek Biosciences's price to earnings ratio for today is 0. PE RATIO(0) = STOCK PRICE($3.76) / TTM EPS($16,603.78)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.